Literature DB >> 19505197

Augmentation of bone growth onto the acetabular cup surface using bone marrow stromal cells in total hip replacement surgery.

Priya Kalia1, Melanie Jean Coathup, Samir Oussedik, Sujith Konan, Matthew Dodd, Fares S Haddad, Gordon W Blunn.   

Abstract

Aseptic loosening of acetabular components in total hip arthroplasty is the major cause of implant failure. Our hypothesis was that spraying autologous bone marrow-derived stromal cells (BMSCs) in fibrin glue onto the surface of hydroxyapatite-coated uncemented acetabular components would increase bone formation and contact in a caprine model. Ten million BMSCs were sprayed onto the acetabular cup at the time of surgery. Animals in the control group received fibrin glue only. Ground reaction force measurements were taken preoperatively and at 6 and 12 weeks postsurgery. After retrieval at 12 weeks new bone formation, bone-implant contact and fibrous tissue thickness adjacent to the cup were quantified. Viability and proliferation assays showed that the majority of the BMSCs survived spraying in fibrin glue at pressures of up to 1.5 atm. New bone growth adjacent to the bone implant interface in the BMSC-treated group (71.42 +/- 8.97%) was 30% greater than in control (54.22 +/- 16.56%) although this difference was not statistically significant. However, significantly increased new bone formation was measured at the periphery of the cup (zone 5) in the BMSC-treated group (71.97 +/- 10.91%) when compared with control (23.85 +/- 15.13%, p = 0.028). Bone-implant contact was significantly greater in the BMSC-treated group (20.03 +/- 4.64%) (control: 13.71 +/- 8.32%, p = 0.027); correspondingly, the average thickness of the fibrous tissue membrane where present was significantly reduced at the periphery of the cups in the BMSC-treated group (327.49 +/- 20.38 mum) when compared with control (887.21 +/- 158.89 mum) (p = 0.02). This study has clinical applications as greater bone contact at the cup surface will improve fixation and may decrease longer-term aseptic loosening by preventing wear debris-induced bone loss at the implant interface.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19505197     DOI: 10.1089/ten.TEA.2008.0676

Source DB:  PubMed          Journal:  Tissue Eng Part A        ISSN: 1937-3341            Impact factor:   3.845


  6 in total

1.  Uncultured marrow mononuclear cells delivered within fibrin glue hydrogels to porous scaffolds enhance bone regeneration within critical-sized rat cranial defects.

Authors:  James D Kretlow; Patrick P Spicer; John A Jansen; Charles A Vacanti; F Kurtis Kasper; Antonios G Mikos
Journal:  Tissue Eng Part A       Date:  2010-10-12       Impact factor: 3.845

2.  Can bone apposition predict the retention force of a femoral stem? An experimental weight-bearing hip-implant model in goats.

Authors:  Knut Harboe; Christian Lycke Ellingsen; Einar Sudmann; Nils Roar Gjerdet; Kjetil Søreide; Kari Indrekvam
Journal:  BMC Musculoskelet Disord       Date:  2015-04-28       Impact factor: 2.362

Review 3.  Hypoxia-inducible factor (HIF): how to improve osseointegration in hip arthroplasty secondary to avascular necrosis in sickle cell disease.

Authors:  Akintunde George; Marianne Ellis; Harinderjit Singh Gill
Journal:  EFORT Open Rev       Date:  2019-09-10

4.  Does the Harvesting Site Influence the Osteogenic Potential of Mesenchymal Stem Cells?

Authors:  Van Thi Nguyen; Irene Tessaro; Antonio Marmotti; Camilla Sirtori; Giuseppe M Peretti; Laura Mangiavini
Journal:  Stem Cells Int       Date:  2019-05-02       Impact factor: 5.443

5.  [Establishment of artificial joint aseptic loosening mouse model by cobalt-chromium particles stimulation].

Authors:  Shengyuan Jiang; Dan Li; Jianhao Jiang; Shangyou Yang; Shuye Yang
Journal:  Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi       Date:  2020-05-15

6.  Tendon Reattachment to Bone in an Ovine Tendon Defect Model of Retraction Using Allogenic and Xenogenic Demineralised Bone Matrix Incorporated with Mesenchymal Stem Cells.

Authors:  Tanujan Thangarajah; Shirin Shahbazi; Catherine J Pendegrass; Simon Lambert; Susan Alexander; Gordon W Blunn
Journal:  PLoS One       Date:  2016-09-08       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.